Patheon unloads some assets on the way to an IPO

Contract drugmaker Patheon is getting out of agrochemicals and selling off a manufacturing plant, narrowing its focus on pharmaceutical development as it plots an IPO. The company sold a plant in Capua, Italy, to German-headquartered industrial outfit Livia, getting rid of a facility that specializes in small molecules and enzymes. Separately, DPx, Patheon's parent company, sold off its agriculture and fine chemicals businesses to Ardian. Meanwhile, Patheon is preparing for a $100 million U.S. IPO. Livia deal | Ardian acquisition

Suggested Articles

Dr. Ian Hudson is stepping down after six years in charge of the Medicines and Healthcare products Regulatory Agency next month.

Oncology tests in the U.S. are still failing to adequately represent racial diversity, and more needs to be done to help combat this disparity.

Symphony Health has inked a new deal with Close-Up International aimed at boosting its global data services.